Clinical Trials Logo
  1. Home
  2. Cytokine Release Syndrome
  3. NCT04048434

Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS) — CYTORELEASE  

Cytokine Release Syndrome Clinical Trial

Official title:
Effectivity of Extracorporeal Cytokine Adsorption (Cytosorb) as Additive Treatment of CAR-T Cell Associated Cytokine Release (CRS) Syndrome and Encephalopathy Syndrome (CRES)

Clinical Trial Summary

Patients with severe CAR-T cell associated cytokine release syndrome (CRS) (defined as vasopressor dependent) will be treated with standard of care (SOC) + cytokine adsorption (6hourly for 24 hrs). Primary endpoint is the change in plasma IL-6 between 0 and 24 hrs.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04048434
Study type Interventional
Source Hannover Medical School
Contact Sascha David, MD
Phone +495115329357
Email david.sascha@mh-hannover.de
Status Recruiting
Phase N/A
Start date June 2021
Completion date September 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT03685383 - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation N/A
Terminated NCT04540120 - Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome Phase 2
Terminated NCT03557749 - Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
Active, not recruiting NCT04150913 - A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity Phase 2
Completed NCT04643678 - Anakinra in the Management of COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04975555 - Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Phase 2
Terminated NCT04403685 - Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers Phase 3
Completed NCT04366908 - Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome Phase 2
Completed NCT05349669 - Jafron Haemoadsorption During Cardiopulmonary Bypass Phase 2
Completed NCT04720378 - Safety and Tolerability Study of IV ST266 in COVID-19 Subjects Phase 1
Terminated NCT04415073 - A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 Phase 2
Completed NCT03533101 - Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation Phase 1/Phase 2
Completed NCT04403061 - Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome
Recruiting NCT05414162 - Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
Terminated NCT04377503 - Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19 Phase 2
Completed NCT04475588 - Efficacy and Safety of Itolizumab in COVID-19 Complications Phase 2
Recruiting NCT04781803 - Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome Phase 2
Completed NCT01353157 - Study of the Clinical Scoring System and Cytokines for Prediction of Inflammatory Response in Major Surgery N/A
Completed NCT04048525 - Cytokine Removal With CVVHD Compared to CVVH N/A
Recruiting NCT04486521 - Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19